About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Prognostic Impact of Frailty in Cardiogenic Shock | Clinical Trials | Clareo Health

Back to clinical trial search

COMPLETEDNCT07260084

Prognostic Impact of Frailty in Cardiogenic Shock

The goal of this observational study is to show prognostic impact of frailty in cardiogenic shock according to age. The main questions it aims to answer are: * Can frailty successfully predict outcom...

Lead sponsor: Samsung Medical Center•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Samsung Medical Center

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Adults aged ≥18 years who were admitted to the intensive care unit (ICU) of tertiary hospitals and were diagnosed with CS

Exclusion Criteria

•Patients diagnosed with anaphylaxis
•Patients with a documented history of shock in the year before the index admission

Related studies

RECRUITINGPhase 1

Safety of BBC1501 Intravitreal Injection in Patients With Neovascular Age-Related Macular Degeneration (nAMD)

NCT05803785 · Age-Related Macular Degeneration

RECRUITINGPhase 3

A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)

NCT07005128 · Small-cell Lung Cancer, Extensive Stage Small-cell Lung Cancer

This Study Investigates β-hydroxy-β-methylbutyrate (HMB) and 2-hydroxybenzylamine (2-HOBA), When Administered Either Individually or in Combination Contributes to an Increased Quality of Health, Specifically Improving Muscular Strength and Cognitive Functioning in Adults Over the Age of 65.

NCT07419633 · Muscle, Cognitive Functioning, and more

RECRUITINGPhase 2

A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)

NCT06064097 · Stage II Nasopharyngeal Carcinoma AJCC v8, Stage III Nasopharyngeal Carcinoma AJCC v8, and more

RECRUITINGPhase 1/2

Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma

NCT06498648 · Advanced Dedifferentiated Liposarcoma, Advanced Leiomyosarcoma, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: December 3, 2025Terms

Trial snapshot

StatusCOMPLETED

Phase—

Enrollment207,419

Start dateJan 2012

Last updatedDec 3, 2025

Condition

Cardiogenic Shock Frailty Age

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 3, 2025Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions